CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.20
-0.09 (-2.74%)
At close: 4:00PM EDT

3.39 +0.19 (5.94%)
Pre-Market: 7:40AM EDT

Stock chart is not supported by your current browser
Previous Close3.29
Open3.29
Bid3.37 x 6100
Ask3.40 x 1500
Day's Range3.17 - 3.29
52 Week Range0.36 - 6.48
Volume108,295
Avg. Volume170,303
Market Cap137.54M
Beta0.64
PE Ratio (TTM)-1.70
EPS (TTM)-1.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • Capital Cube8 days ago

    ETFs with exposure to CTI BioPharma Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube22 days ago

    ETFs with exposure to CTI BioPharma Corp. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
    Capital Cube25 days ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 22.23 million, Net Earnings of USD 5.40 million. Gross margins widened from 96.40% to 98.80% compared to the same period last year, operating (EBITDA) margins now 33.57% from -256.17%. Change in operating ... Read more (Read more...)

  • CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
    PR Newswire28 days ago

    CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions

    SEATTLE, Sept. 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed its new Chairman of the Board and the promotion of David H. Kirske to Chief Financial Officer and Bruce J. Seeley to Chief Operating Officer of the company. "The appointments announced today strengthen and solidify our board and leadership at an important time for the company," said Adam R. Craig, M.D., Ph.D., President and CEO of CTI BioPharma. "I am pleased to serve as Chairman as the changes taking place at the company provide the opportunity to deliver on the commitment to patients and shareholders," said Dr. Fischer.

  • PR Newswire2 months ago

    CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference

    SEATTLE , Aug. 31, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the 24th Annual BioCentury NewsMakers in the Biotech Industry ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT

    Q2 2017 CTi Biopharma Corp Earnings Call

  • Associated Press3 months ago

    CTI BioPharma posts 2Q profit

    The Seattle-based company said it had profit of 3 cents per share. Earnings, adjusted for stock option expense, came to 6 cents per share. The biotechnology company posted revenue of $22.2 million in the ...

  • CTI BioPharma Reports Second Quarter 2017 Financial Results
    PR Newswire3 months ago

    CTI BioPharma Reports Second Quarter 2017 Financial Results

    -PAC203 Phase 2 Trial of Pacritinib Initiated -Marketing Authorization Application for Pacritinib Under Review by European Medicines Agency -Enrollment Completed in the PIX306 Phase 3 Trial of PIXUVRI® ...

  • ACCESSWIRE3 months ago

    Investor Network: CTI BioPharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 3, 2017 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM Eastern ...

  • CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
    PR Newswire3 months ago

    CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma

    SEATTLE, Aug. 2, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced the completion of enrollment in the Phase 3 PIX306 trial of PIXUVRI® (pixantrone). The PIX306 trial is evaluating PIXVURI combined with rituximab in comparison to that of rituximab combined with gemcitabine in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). Patients eligible to be enrolled in the trial had failed front line CHOP-R and were not eligible for autologous stem cell transplant (ASCT) (2nd line) or failed ASCT (3rd or 4th line).

  • CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
    PR Newswire3 months ago

    CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib

    SEATTLE, Aug. 1, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that the first patient has been enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. PAC203 is designed to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in the Phase 3 PERSIST-2 trial of pacritinib in patients with myelofibrosis.

  • CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
    PR Newswire3 months ago

    CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017

    SEATTLE , July 27, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its second quarter 2017 financial results on Thursday, ...

  • CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
    PR Newswire3 months ago

    CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors

    SEATTLE, July 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed a Director of CTI BioPharma effective July 21, 2017. Dr. Fischer  has more than 20 years experience in developing and commercializing novel medicines in the biopharmaceutical industry and currently serves as liver therapeutic area head at Allergan following its acquisition of Tobira Therapeutics in 2016 where he previously served as Chief Executive Officer.

  • CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
    PR Newswire3 months ago

    CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia

    SEATTLE, July 13, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). Validation confirms that the submission is complete and initiates the centralized review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).  The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on EU authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 EU member states.

  • PR Newswire4 months ago

    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    SEATTLE , June 15, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to ...

  • Capital Cube5 months ago

    ETFs with exposure to CTI BioPharma Corp. : June 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
    PR Newswire5 months ago

    CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock

    SEATTLE, June 6, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the "Offering"). Each share of Series N-3 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $3.00  per share of common stock, for a total of approximately 15.0 million shares of common stock.

  • CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
    PR Newswire5 months ago

    CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock

    SEATTLE, June 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-3 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-3 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance and subject to certain limitations, into shares of common stock. CTI plans to use the net proceeds from this Offering to conduct the PAC203 clinical trial, submit a new Marketing Authorization Application for pacritinib to the European Medicines Agency, conduct additional research concerning the possible application of pacritinib in indications outside of myelofibrosis, and complete the PIX306 clinical trial, as well as for general corporate purposes, which may include funding research and development, conducting preclinical and clinical trials, acquiring or in-licensing potential new pipeline candidates, preparing and filing possible new drug applications and general working capital.

  • CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations
    PR Newswire5 months ago

    CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations

    SEATTLE, June 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that David R. Parkinson, M.D., has been appointed a Director of CTI BioPharma effective June 5, 2017. Dr. Parkinson has more than 20 years in oncology clinical development with executive leadership roles at major biotechnology and pharmaceutical companies. Additionally, Phillip M. Nudelman, Ph.D., has resigned as a member of the Board of Directors due to health reasons.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT

    Q1 2017 CTi Biopharma Corp Earnings Call

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
    Capital Cube6 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Novartis AG Sponsored ADR, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Incyte Corporation and Celgene Corporation (NVS-US, LLY-US, AMGN-US, ... Read more (Read more...)

  • Associated Press6 months ago

    CTI BioPharma reports 1Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 71 cents. Losses, adjusted for stock option expense, came to 65 cents per share. The biotechnology company posted revenue of $754,000 ...

  • CTI BioPharma Reports First Quarter 2017 Financial Results
    PR Newswire6 months ago

    CTI BioPharma Reports First Quarter 2017 Financial Results

    SEATTLE, May 3, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2017. Recent Highlights In April 2017, CTI BioPharma ...

  • CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017
    PR Newswire6 months ago

    CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017

    SEATTLE, April 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its first quarter 2017 financial results on Wednesday, ...

  • Capital Cube6 months ago

    ETFs with exposure to CTI BioPharma Corp. : April 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)